[Drug treatment for children with cerebral palsy]

Hilla Ben-Pazi1

  • 1Pediatric Movement Disorders, Department of Child Neurology, Stanford Medical Center, CA 94305-5235, USA. shmaryaho@hotmail.com

Harefuah
|August 12, 2006
PubMed

Insights

Cerebral palsy (CP) management focuses on muscle hypertonia, including spasticity and dystonia. This review details drug treatments like Baclofen, Botulinum toxin, Dopamine, and Trihexyphenidyl for improved motor control in children with CP.

Area of Science:

  • Neurology
  • Pediatrics
  • Pharmacology

Context:

  • Cerebral palsy (CP) is a leading cause of childhood immobility.
  • Motor dysfunction in CP involves weakness, poor motor control, and muscle hypertonia.
  • Recent definitions aid in distinguishing spasticity and dystonia in CP.

Purpose:

  • To review current drug treatments for muscle hypertonia in cerebral palsy.
  • To highlight specific medications for spasticity and dystonia.
  • To emphasize individualized, team-based approaches to CP management.

Summary:

  • Drug treatments primarily target muscle hypertonia in cerebral palsy.
  • Baclofen is used for general spasticity.
  • Botulinum toxin is effective for localized spasticity or dystonia.
  • Dopamine and Trihexyphenidyl are considered for generalized dystonia.

Impact:

  • Provides an overview of pharmacological interventions for CP.
  • Facilitates informed treatment decisions for healthcare providers.
  • Aims to improve daily function and motor control in children with CP.

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.